By using quartiles (Q) for PD-L1 TPS (Q1: ≤1% vs. Q2–Q4: >1%), a statistically significant survival advantage for rectal cancer patients with higher PD-L1 TPS prior to neoadjuvant CRT was shown (median OS: not reached vs. 95.4 months (95% CI: 51.8—not reached), p = 0.03, Figure 3A). Here, CD274 is linked to rectal cancer.